Short answer
Replimune Group, Inc. (REPL) filed an 8-K current report with the SEC on July 31, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA Advisory Committee reviewed RP1 BLA resubmission with nivolumab for advanced melanoma.
Replimune Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA Advisory Committee reviewed RP1 BLA resubmission with nivolumab for advanced melanoma
- Committee voted 10–3 that IGNYTE efficacy results are evaluable and clinically meaningful
- Favorable advisory vote supports Replimune’s regulatory case, though FDA retains final approval authority
- Outcome could materially influence RP1’s commercialization prospects and Replimune’s valuation
Item EX-99.1 · Exhibit EX-99.1
- FDA advisory committee voted 10–3 that RP1’s IGNYTE efficacy results are evaluable and clinically meaningful
- Positive vote supports Replimune’s BLA resubmission for RP1 plus nivolumab in advanced melanoma after prior anti-PD-1 therapy
- FDA target action date: August 2, 2026, creating a near-term approval decision catalyst
- Advisory vote is nonbinding, leaving final approval dependent on FDA’s ongoing review
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Replimune Group, Inc. 8-K filings
Get the next REPL 8-K as it lands
Follow REPL for push alerts, or ask the research agent what this filing means.